Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation

Cancer Immunology, Immunotherapy

Volumn 61, Issue 2, 2012, Pages 275-282

  Umansky, Viktor ^a   Sevko, Alexandra ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic inflammation; CITIM 2011; Immunosuppression; Melanoma; Myeloid derived suppressor cells; Tumor microenvironment

Indexed keywords

CD11B ANTIGEN; CELL PROTEIN; DENDRITIC CELL VACCINE; PACLITAXEL; PROTEIN GR1; SILDENAFIL; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; TADALAFIL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL HETEROGENEITY; CELL INFILTRATION; CHRONIC INFLAMMATION; DRUG EFFICACY; ERECTILE DYSFUNCTION; HEART HYPERTROPHY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOPATHOGENESIS; LEUKOCYTE; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; MEDIATOR RELEASE; MELANOMA; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; ONCOGENE RET; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; SKIN MELANOMA; SUPPRESSOR CELL; T CELL DEPLETION; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION; MELANOMA; MICE; MICE, KNOCKOUT; PACLITAXEL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-RET; PURINES; RECEPTORS, ANTIGEN, T-CELL; SULFONES; TUMOR MICROENVIRONMENT; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84856760496     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1164-6     Document Type: Review

References (76)

1. RM MacKie A Hauschild AM Eggermont 2009 Epidemiology of invasive cutaneous melanoma Ann Oncol 20 Suppl 6 vi1 vi7 19617292 10.1093/annonc/mdp252
2. C Garbe K Peris A Hauschild P Saiag M Middleton A Spatz JJ Grob J Malvehy J Newton-Bishop A Stratigos H Pehamberger A Eggermont 2010 Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline Eur J Cancer 46 270 283 19959353 10.1016/j.ejca.2009.10.032
3. MK Callahan JD Wolchok JP Allison 2010 Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy Semin Oncol 37 473 484 21074063 10.1053/j.seminoncol.2010.09.001 1:CAS:528: DC%2BC3cXhsVWrur7M
4. F Pandolfi R Cianci S Lolli IS Dunn EE Newton TJ Haggerty LA Boyle JT Kurnick 2008 Strategies to overcome obstacles to successful immunotherapy of melanoma Int J Immunopathol Pharmacol 21 493 500 18831916 1:CAS:528: DC%2BD1cXht1ygs7zN
5. G Parmiani C Castelli M Santinami L Rivoltini 2007 Melanoma immunology: past, present and future Curr Opin Oncol 19 121 127 17272984 10.1097/CCO.0b013e32801497d7 (Pubitemid 46204351)
6. S Fujii K Shimizu H Hemmi RM Steinman 2007 Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity Immunol Rev 220 183 198 17979847 10.1111/j.1600-065X.2007.00561.x 1:CAS:528:DC%2BD2sXhsVKgtrvO (Pubitemid 350045564)
7. J Dissemond T Kothen J Mörs TK Weimann A Lindeke M Goos SN Wagner 2003 Downregulation of tapasin expression in progressive human malignant melanoma Arch Dermatol Res 295 43 49 12682852 10.1007/s00403-003-0393-8 1:CAS:528:DC%2BD3sXmsV2lt7k%3D (Pubitemid 36791722)
8. S Ferrone FM Marincola 1995 Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance Immunol Today 16 487 494 7576053 10.1016/0167-5699(95)80033-6 1:CAS:528:DyaK2MXosFGju7o%3D
9. S Burke T Lakshmikanth F Colucci E Carbone 2010 New views on natural killer cell-based immunotherapy for melanoma treatment Trends Immunol 31 339 345 20655806 10.1016/j.it.2010.06.003 1:CAS:528:DC%2BC3cXhtFals7rF
10. S Ostrand-Rosenberg 2008 Immune surveillance: a balance between protumor and antitumor immunity Curr Opin Genet Dev 18 11 18 18308558 10.1016/j.gde.2007.12.007 1:CAS:528:DC%2BD1cXmsVartLc%3D (Pubitemid 351694442)
11. E Lázár-Molnár H Hegyesi S Tóth A Falus 2000 Autocrine and paracrine regulation by cytokines and growth factors in melanoma Cytokine 12 547 554 10843728 10.1006/cyto.1999.0614 (Pubitemid 30453481)
12. + T regulatory cells, immunotherapy of cancer, and interleukin-2 J Immunother 28 120 128 15725955 10.1097/01.cji.0000155049.26787.45 1:CAS:528:DC%2BD2MXhsFSmurg%3D (Pubitemid 40328198)
13. W Zou 2005 Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 5 263 274 15776005 10.1038/nrc1586 1:CAS:528:DC%2BD2MXivVars7g%3D (Pubitemid 40488632)
14. DI Gabrilovich S Nagaraj 2009 Myeloid-derived suppressor cells as regulators of the immune system Nat Rev Immunol 9 162 174 19197294 10.1038/nri2506 1:CAS:528:DC%2BD1MXhsFeqsbw%3D
15. S Ostrand-Rosenberg 2010 Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity Cancer Immunol Immunother 59 1593 1600 20414655 10.1007/s00262-010-0855-8
16. MR Shurin H Naiditch H Zhong GV Shurin 2011 Regulatory dendritic cells: new targets for cancer immunotherapy Cancer Biol Ther 11 988 992 21474998 10.4161/cbt.11.11.15543
17. Y Ben-Neriah M Karin 2011 Inflammation meets cancer, with NF-κB as the matchmaker Nat Immunol 12 715 723 21772280 10.1038/ni.2060 1:CAS:528:DC%2BC3MXptV2isrk%3D
18. GA Rook A Dalgleish 2011 Infection, immunoregulation, and cancer Immunol Rev 240 141 159 21349092 10.1111/j.1600-065X.2010.00987.x 1:CAS:528: DC%2BC3MXktFehtr4%3D
19. DW Cramer OJ Finn 2011 Epidemiologic perspective on immune-surveillance in cancer Curr Opin Immunol 23 265 271 21277761 10.1016/j.coi.2011.01.002 1:CAS:528:DC%2BC3MXkt1Kitro%3D
20. A Mantovani 2010 Molecular pathways linking inflammation and cancer Curr Mol Med 10 369 373 20455855 10.2174/156652410791316968 1:CAS:528: DC%2BC3cXmsVamsb4%3D
21. P Allavena G Germano F Marchesi A Mantovani 2011 Chemokines in cancer related inflammation Exp Cell Res 317 664 673 21134366 10.1016/j.yexcr.2010.11. 013 1:CAS:528:DC%2BC3MXjsFaitrw%3D
22. M Baniyash 2006 Chronic inflammation, immunosuppression and cancer: new insights and outlook Semin Cancer Biol 16 80 88 16420981 10.1016/j.semcancer. 2005.12.002 1:CAS:528:DC%2BD28XotVClsA%3D%3D (Pubitemid 43139712)
23. TT Tan LM Coussens 2007 Humoral immunity, inflammation and cancer Curr Opin Immunol 19 209 216 17276050 10.1016/j.coi.2007.01.001 1:CAS:528: DC%2BD2sXislehsr4%3D (Pubitemid 46356960)
24. A Sparmann D Bar-Sagi 2004 Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis Cancer Cell 6 447 458 15542429 10.1016/j.ccr.2004.09.028 1:CAS:528:DC%2BD2cXhtVGlurvE (Pubitemid 39469981)
25. H Sumimoto F Imabayashi T Iwata Y Kawakami 2006 The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells J Exp Med 203 1651 1656 16801397 10.1084/jem.20051848 1:CAS:528:DC%2BD28XntVCgsrg%3D (Pubitemid 44036269)
26. F Haluska T Pemberton N Ibrahim K Kalinsky 2007 The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications Semin Oncol 34 546 554 18083378 10.1053/j.seminoncol.2007.09.011 1:CAS:528:DC%2BD1cXht1aqtrw%3D (Pubitemid 350236312)
27. J Lomas P Martin-Duque M Pons M Quintanilla 2008 The genetics of malignant melanoma Front Biosci 13 5071 5093 18508571 10.2741/3065 1:CAS:528:DC%2BD1cXnsVOjt7c%3D (Pubitemid 351599659)
28. M Kato M Takahashi AA Akhand W Liu Y Dai S Shimizu T Iwamoto H Suzuki I Nakashima 1999 Transgenic mouse model for skin malignant melanoma Oncogene 17 1885 1888 10.1038/sj.onc.1202077
29. C Eng 1999 RET proto-oncogene in the development of human cancer J Clin Oncol 17 380 383 10458257 1:CAS:528:DyaK1MXltVyrtQ%3D%3D
30. V Umansky O Abschuetz W Osen M Ramacher F Zhao M Kato D Schadendorf 2008 Melanoma-specific memory T cells are functionally active in ret transgenic mice without macroscopic tumors Cancer Res 68 9451 9458 19010920 10.1158/0008-5472. CAN-08-1464 1:CAS:528:DC%2BD1cXhtlOmt7jJ
31. A Houghton D Polsky 2002 Focus on melanoma Cancer Cell 2 275 278 12398891 10.1016/S1535-6108(02)00161-7 1:CAS:528:DC%2BD38Xot1Gkt70%3D (Pubitemid 41043961)
32. F Zhao C Falk W Osen M Kato D Schadendorf V Umansky 2009 Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma Clin Cancer Res 15 4382 4390 19549770 10.1158/1078-0432.CCR-09-0399 1:CAS:528: DC%2BD1MXnvFajtrw%3D
33. C Meyer A Sevko M Ramacher AV Bazhin CS Falk W Osen I Borrello M Kato D Schadendorf M Baniyash V Umansky 2011 Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model Proc Natl Acad Sci USA 108 17111 17116 21969559 10.1073/pnas.1108121108 1:CAS:528:DC%2BC3MXhtlCksLnI
34. S Kimpfler A Sevko S Ring C Falk W Osen K Frank M Kato K Mahnke D Schadendorf V Umansky 2009 Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs J Immunol 183 6330 6337 19841169 10.4049/jimmunol.0900609 1:CAS:528: DC%2BD1MXhtlKhsbbP
35. I Marigo E Bosio S Solito C Mesa A Fernandez L Dolcetti S Ugel N Sonda S Bicciato E Falisi F Calabrese G Basso P Zanovello E Cozzi S Mandruzzato V Bronte 2010 Tumor-induced tolerance and immune suppression depend on the C/EBPb transcription factor Immunity 32 790 802 20605485 10.1016/j.immuni.2010.05.010 1:CAS:528:DC%2BC3cXovVahtbc%3D
36. N Bronstein-Sitton I Vaknin AV Ezernitchi B Leshem A Halabi Y Houri-Hadad E Greenbaum Z Zakay-Rones L Shapira M Baniyash 2003 Sustained exposure to bacterial antigen induces interferon gamma-dependent T cell receptor zeta down-regulation and impaired T cell function Nat Immunol 4 957 964 14502285 10.1038/ni975 1:CAS:528:DC%2BD3sXnsF2mu74%3D (Pubitemid 37270574)
37. S Rössner C Voigtländer C Wiethe J Hänig C Seifarth MB Lutz 2005 Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro Eur J Immunol 35 3533 3544 16331707 10.1002/eji.200526172 (Pubitemid 43025534)
38. MJ Delano PO Scumpia JS Weinstein D Coco S Nagaraj KM Kelly-Scumpia KA O'Malley JL Wynn S Antonenko SZ Al-Quran R Swan CS Chung MA Atkinson R Ramphal DI Gabrilovich WH Reeves A Ayala J Phillips D Laface PG Heyworth M Clare-Salzler LL Moldawer 2007 MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis J Exp Med 204 1463 1474 17548519 10.1084/jem.20062602 1:CAS:528:DC%2BD2sXms1aktLg%3D (Pubitemid 46919883)
39. E Peranzoni S Zilio I Marigo L Dolcetti P Zanovello S Mandruzzato V Bronte 2010 Myeloid-derived suppressor cell heterogeneity and subset definition Curr Opin Immunol 22 238 244 20171075 10.1016/j.coi.2010.01.021 1:CAS:528:DC%2BC3cXks1Srtr0%3D
40. V Bronte P Zanovello 2005 Regulation of immune responses by l-arginine metabolism Nat Rev Immunol 5 641 654 16056256 10.1038/nri1668 1:CAS:528:DC%2BD2MXmvVClsLc%3D (Pubitemid 41113195)
41. PC Rodríguez AC Ochoa 2006 T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress Semin Cancer Biol 16 66 72 16298138 10.1016/j.semcancer.2005.10.001 (Pubitemid 43139710)
42. V Umansky V Schirrmacher 2001 Nitric oxide-induced apoptosis in tumor cells Adv Cancer Res 82 107 131 11447761 10.1016/S0065-230X(01)82004-2 1:CAS:528:DC%2BD3MXls1aktbg%3D (Pubitemid 32613384)
43. C Bogdan 2001 Nitric oxide and the immune response Nat Immunol 2 907 916 11577346 10.1038/ni1001-907 1:CAS:528:DC%2BD3MXnsVCisrs%3D (Pubitemid 32976162)
44. S Nagaraj AG Schrum HI Cho E Celis DI Gabrilovich 2010 Mechanism of T cell tolerance induced by myeloid-derived suppressor cells J Immunol 184 3106 3116 20142361 10.4049/jimmunol.0902661 1:CAS:528:DC%2BC3cXis1yitrs%3D
45. B Molon S Ugel F Del Pozzo C Soldani S Zilio D Avella A De Palma P Mauri A Monegal M Rescigno B Savino P Colombo N Jonjic S Pecanic L Lazzarato R Fruttero A Gasco V Bronte A Viola 2011 Chemokine nitrosylation prevents intratumoral infiltration of antigen-specific T cells J Exp Med 208 1949 1962 21930770 10.1084/jem.20101956 1:CAS:528:DC%2BC3MXht1KjsbnI
46. MK Srivastava P Sinha VK Clements P Rodriguez S Ostrand-Rosenberg 2010 Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine Cancer Res 70 68 77 20028852 10.1158/0008-5472.CAN-09-2587 1:CAS:528:DC%2BC3cXltVaj
47. + T cells J Immunol 183 937 944 19553533 10.4049/jimmunol.0804253 1:CAS:528:DC%2BD1MXotFWgtLc%3D
48. P Filipazzi R Valenti V Huber L Pilla P Canese M Iero C Castelli L Mariani G Parmiani L Rivoltini 2007 Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine J Clin Oncol 25 2546 2553 17577033 10.1200/JCO.2006.08.5829 1:CAS:528: DC%2BD2sXotV2mt7Y%3D (Pubitemid 47041228)
49. I Poschke D Mougiakakos J Hansson GV Masucci R Kiessling 2010 Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign Cancer Res 70 4335 4345 20484028 10.1158/0008-5472.CAN-09-3767 1:CAS:528:DC%2BC3cXmslWgsbY%3D
50. AV Ezernitchi I Vaknin L Cohen-Daniel O Levy E Manaster A Halabi E Pikarsky L Shapira M Baniyash 2006 TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs J Immunol 177 4763 4772 16982917 1:CAS:528:DC%2BD28Xps1Gns7w%3D (Pubitemid 44469811)
51. PC Rodríguez AH Zea KS Culotta J Zabaleta JB Ochoa AC Ochoa 2002 Regulation of T cell receptor CD3zeta chain expression by l-arginine J Biol Chem 277 21123 21129 11950832 10.1074/jbc.M110675200 (Pubitemid 34952247)
52. M Baniyash 2004 TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response Nat Rev Immunol 4 675 687 15343367 10.1038/nri1434 1:CAS:528:DC%2BD2cXntFCmt7Y%3D (Pubitemid 39223074)
53. S Ishigami S Natsugoe K Tokuda A Nakajo H Higashi H Iwashige K Aridome S Hokita T Aikou 2002 CD3-zeta chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients Cancer 94 1437 1442 11920499 10.1002/cncr.10346 1:CAS:528:DC%2BD38XisVWmtL4%3D (Pubitemid 34212637)
54. TL Whiteside 2004 Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53 865 878 15118842 1:CAS:528:DC%2BD2cXntV2hsLs%3D (Pubitemid 39312654)
55. S Ugel F Delpozzo G Desantis F Papalini F Simonato N Sonda S Zilio V Bronte 2009 Therapeutic targeting of myeloid-derived suppressor cells Curr Opin Pharmacol 9 470 481 19616475 10.1016/j.coph.2009.06.014 1:CAS:528: DC%2BD1MXhtVenurbF
56. N Mirza M Fishman I Fricke M Dunn AM Neuger TJ Frost RM Lush S Antonia DI Gabrilovich 2006 All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients Cancer Res 66 9299 9307 16982775 10.1158/0008-5472.CAN-06-1690 1:CAS:528:DC%2BD28Xps1ahsrk%3D (Pubitemid 44521152)
57. PY Pan GX Wang B Yin J Ozao T Ku CM Divino SH Chen 2008 Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function Blood 111 219 228 17885078 10.1182/blood-2007-04-086835 1:CAS:528:DC%2BD1cXjtVKitg%3D%3D
58. J Vincent G Mignot F Chalmin S Ladoire M Bruchard A Chevriaux F Martin L Apetoh C Rébé F Ghiringhelli 2010 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res 70 3052 3061 20388795 10.1158/0008-5472.CAN-09-3690 1:CAS:528:DC%2BC3cXkslShsLk%3D
59. E Suzuki V Kapoor AS Jassar LR Kaiser SM Albelda 2005 Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin Cancer Res 11 6713 6721 16166452 10.1158/1078-0432.CCR-05-0883 1:CAS:528:DC%2BD2MXhtVShsb3O (Pubitemid 41339014)
60. P Serafini K Meckel M Kelso K Noonan J Califano W Koch L Dolcetti V Bronte I Borrello 2006 Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function J Exp Med 203 2691 2702 17101732 10.1084/jem.20061104 1:CAS:528:DC%2BD28Xht12htLfL (Pubitemid 44833345)
61. C De Santo P Serafini I Marigo L Dolcetti M Bolla P Del Soldato C Melani C Guiducci MP Colombo M Iezzi P Musiani P Zanovello V Bronte 2005 Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination Proc Natl Acad Sci USA 102 4185 4190 15753302 10.1073/pnas.0409783102 (Pubitemid 40388577)
62. P Sinha VK Clements S Ostrand-Rosenberg 2005 Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease J Immunol 174 636 645 15634881 1:CAS:528:DC%2BD2MXotFSg (Pubitemid 40094255)
63. HA Ghofrani IH Osterloh F Grimminger 2006 Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond Nat Rev Drug Discov 5 689 702 16883306 10.1038/nrd2030 1:CAS:528:DC%2BD28XnsFCkuro%3D (Pubitemid 44151606)
64. P Serafini S Mgebroff K Noonan I Borrello 2008 Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells Cancer Res 68 5439 5449 18593947 10.1158/0008-5472.CAN-07-6621 1:CAS:528:DC%2BD1cXnvFyjur4%3D
65. G Capuano N Rigamonti M Grioni M Freschi M Bellone 2009 Modulators of arginine metabolism support cancer immunosurveillance BMC Immunol 10 1 19134173 10.1186/1471-2172-10-1
66. P Cheng CA Corzo N Luetteke B Yu S Nagaraj MM Bui M Ortiz W Nacken C Sorg T Vogl J Roth DI Gabrilovich 2008 Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein J Exp Med 205 2235 2249 18809714 10.1084/jem.20080132 1:CAS:528:DC%2BD1cXht1SrtLvE
67. P Sinha C Okoro D Foell HH Freeze S Ostrand-Rosenberg G Srikrishna 2008 Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells J Immunol 181 4666 4675 18802069 1:CAS:528:DC%2BD1cXhtFarurzK
68. E Tartour H Pere B Maillere M Terme N Merillon J Taieb F Sandoval F Quintin-Colonna K Lacerda A Karadimou C Badoual A Tedgui WH Fridman S Oudard 2011 Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy Cancer Metastasis Rev 30 83 95 21249423 10.1007/s10555-011-9281-4 1:CAS:528:DC%2BC3MXitlKltL8%3D
69. A Laties E Zrenner 2002 Viagra (sildenafil citrate) and ophthalmology Prog Retin Eye Res 21 485 506 12207947 10.1016/S1350-9462(02)00013-7 1:CAS:528:DC%2BD38Xms1Kiurk%3D (Pubitemid 35245968)
70. AK Nowak RA Lake BW Robinson 2006 Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 58 975 990 17005292 10.1016/j.addr.2006.04.002 1:CAS:528:DC%2BD28Xht1Sht7bE (Pubitemid 44780907)
71. L Zitvogel O Kepp G Kroemer 2011 Immune parameters affecting the efficacy of chemotherapeutic regimens Nat Rev Clin Oncol 8 151 160 21364688 10.1038/nrclinonc.2010.223 1:CAS:528:DC%2BC3MXis1Cgtb4%3D
72. R Kaneno GV Shurin FM Kaneno H Naiditch J Luo MR Shurin 2011 Chemotherapeutic agents in low non-cytotoxic concentrations increase immunogenicity of human colon cancer cells Cell Oncol (Dordr) 34 97 106 1:CAS:528:DC%2BC3MXnsVSgtro%3D
73. R Kaneno GV Shurin IL Tourkova MR Shurin 2009 Chemomodulation of human dendritic cell function by anti-neoplastic agents in low non-cytotoxic concentrations J Transl Med 7 58 19591684 10.1186/1479-5876-7-58
74. GV Shurin IL Tourkova R Kaneno MR Shurin 2009 Chemotherapeutic agents in non-cytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism J Immunol 183 137 144 19535620 10.4049/jimmunol.0900734 1:CAS:528:DC%2BD1MXnsVOrtb8%3D
75. GV Shurin IL Tourkova MR Shurin 2008 Low-dose chemotherapeutic agents regulate small rho GTPase activity in dendritic cells J Immunother 31 491 499 18463535 10.1097/CJI.0b013e318176fae4 1:CAS:528:DC%2BD1cXmsFyrs7g%3D
76. H Zhong B Han IL Tourkova A Lokshin A Rosenbloom MR Shurin GV Shurin 2007 Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth Clin Cancer Res 13 5455 5462 17875775 10.1158/1078-0432.CCR-07-0517 1:CAS:528:DC%2BD2sXhtVCitL3M (Pubitemid 47510373)